Skip to main content
. 2022 Mar 9;16(3):e0010115. doi: 10.1371/journal.pntd.0010115

Table 3. Factors associated with changes in ShTAL1 IgE response over the study period.

Factor ShTAL1-specific IgE (Responder vs. non-responder)
cOR (95% CI) P-value of interaction aOR (95% CI) Wald’s P-value
S.haematobium. Infection * Treatment
S. h. positive * Baseline 1.74 (0.40–7.49) 0.458 - -
S. h. negative * Baseline 1.00 (0.00) - - -
S. h. positive * Follow-up 13.33 (1.58–112.01) 0.017 6.16 (0.71–53.59) 0.099
S. h. negative * Follow-up 3.81 (1.84–7.89) <0.001 5.38 (2.48–11.64) <0.001
STH Infection status
Negative 1 - 1 -
Positive 1.00 (0.00) 1.00 3.94 (0.57–27.14) 0.16
Age (years)
6–11 1 - 1 -
12–14 9.64 (2.09–44.51) 0.004 22.34 (2.77–180.14) 0.004
≥ 15 14.26 (3.10–65.51) 0.001 51.82 (6.44–417.17) <0.001
Gender
Male 1 - 1
Female 0.53 (0.22–1.28) 0.16 0.51 (0.17–1.52) 0.225
P. falciparum infection status
Negative 1 - 1 -
Positive 4.66 (1.69–12.79) 0.003 2.14 (0.98–4.69) 0.058

The Generalized Estimating Equation was used in determining the association of factors with ShTAL1 IgE response frequencies at baseline and at Follow-up (i.e. 7 weeks post-PZQ treatment). A product term was employed to assess the combined effect of S. haematobium infection status and treatment on ShTAL1 IgE positivity. cOR = crude Odds Ratio; aOR = adjusted Odds ratio; STH = soil-transmitted helminths comprising Ascaris lumbircoides, and Trichuris trichiura; ShTAL1 = S. haematobium-specific tegumental allergen-like protein 1. Significant values are in boldface.